Resonance Health develops and commercialises technologies and services for the quantitative analysis of radiological images in a regulated and quality controlled environment. Co.'s principal product is FerriScan®, a non-invasive liver diagnostic technology used for the measurement of iron in the liver. Another product of Co., HepaFat-Scan®, provides a measurement of volumetric liver fat fraction. Co.'s product pipeline, both developed and under development, include technologies for application in additional organs including the bone marrow, pancreas, and spleen, as well as tools for non-invasive measurement of liver fibrosis and inflammation.
Ford US Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.